Erectile dysfunction;Disfunción eréctil

Actas Urologicas Espanolas

Volumn 26, Issue 9, 2002, Pages 667-690

  Rodriguez Vela L ^a,b   Gonzalvo Ibarra, A ^a   Pascual Regueiro, D ^a   Rioja Sanz, L A ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b NONE   (Spain)

Author keywords

Erectile dysfunction: Aethiopathogeny, Diagnosis. Treatment. Impotence

Indexed keywords

APOMORPHINE; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; TESTOSTERONE; VARDENAFIL;

ANAMNESIS; ARTERIOSCLEROSIS; DIABETES MELLITUS; DRUG EFFICACY; ERECTILE DYSFUNCTION; HUMAN; LABORATORY TEST; MALE; PENIS PROSTHESIS; PHYSICAL EXAMINATION; PSYCHOTHERAPY; REVASCULARIZATION; REVIEW; RISK FACTOR; SUBSTITUTION THERAPY;

EID: 0036813071     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0210-4806(02)72844-1     Document Type: Review

References (75)

1. Erectile Dysfunction. World Health Organization. Health Publication Ltd. Plymouth. Oxford. United Kingdom 2000.
2. Martín-Morales A, Sánchez-Cruz JJ, Sáenz De Tejada I, Rodríguez-Vela L, Jiménez-Cruz JF, Burgos-Rodríguez R.: Prevalence and independent risk factors for erectile dysfunction in spain. Results of the EDEM study (epidemiología de la disfunción eréctil masculina). J Urol 2001; 166 (2): 569-574.
3. Felman HA, Goldstein I, Hatzichristou D, Krane RJ, Mckinlay JB.: Impotence and its medical and psychosocial correlates: Results of the Massachusetts male aging study. J Urol 1994; 151: 54.
4. Lue T.: Evaluation and nonsurgical management of erectile dysfunction and priapism. In: Campbell's Urology. W.B. Saunders Co, Filadelfia 1998.
5. Lue T.: Erectile dysfunction. N Engl J Med 2000, 342 (24): 1.802-1.813.
6. Krane RJ, Goldstein I, Sáenz De Tejada I.: Impotence. N Engl J Med 1989, 321: 1.648-1.659.
7. Sáenz De Tejada I, Goldstein I, Krane RJ.: Regulation of adrenergic activity in penile corpus cavernosum. J Urol 1989; 142: 1.117-1.121.
8. Lue T, Tanagho EA.: Hemodinamics of erection. In: Tanagho EA, Lue T, McClure RD, eds. Contemporary Management of Impotence and Infertility: 28-38. Baltimore: Williams & Wilkins 1988.
9. Sáenz De Tejada I.: Fisiología de la erección. En: Disfunción Eréctil: Diagnóstico y Tratamiento: 27. (L. Rodríguez Vela Ed.) Tema Monográfico Asociación Española de Urología. Madrid: Ene Ediciones 1993.
10. Kim N, Azadzoi KM, Goldstein I, Sáenz De Tejada I.: A nitric oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle. J Clin Invest 1991; 88: 112-118.
11. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J.: Nitric oxide and cyclic GMP formation upon electrical stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1990; 170: 843-850.
12. Kinsey AC.: Age and sexual oulet. En: Sexual Behaviour in the Human Male: 218. Philadelphia: WB Saunders, 1948.
13. Schiavi RC, White D.: Androgens and male sexual function: A review of human studies. J Sex Marital Ther 1976; 2: 214.
14. Rodríguez Vela L, Sáenz De Tejada I.: Epidemiología y etiopatogenia de la disfunción eréctil. En: I. Sáenz de Tejada, A. Allona, eds. Erección, eyaculación y sus trastornos. Madrid: Fomento Salud, 1997.
15. Martín Morales A, Díaz F, García E.: Epidemiología y etiopatogenia de la disfunción eréctil. En: Rodríguez Vela, L. y Rioja Sanz, L.A. eds. Actualización en Andrología. Ed. Pulso. Barcelona, 2000.
16. Persson C, Diederichs W, Lue TF, Yen B, Fishman IJ, Mclin H, Tanagho EA.: Correlation of altered penile ultrastructure with clinical arterial evaluation. J Urol 1989; 142: 1.462.
17. Azadzoi K, Goldstein I.: Erectile dysfunction due to atherosclerotic vascular disease: The development of an animal model. J Urol 1992; 147: 1.675.
18. Moreland R, Traish A, Goldstein I, Sáenz De Tejada I.: PGE1 supresses the induction of new collagen synthesis by transforming growth factor beta 1 in human corpus cavernosum smooth muscle: Mechanism of penile ischemia associated fibrosis. J Urol 1995; 153: 826.
19. Mcvary KT, Carrier S, Wessells H.: Smoking and erectile dysfunction: Evidence based analysis. J Urol 2001; 166: 1.624-1.632.
20. Wein AJ, Van Arsdalen.: Drug-induced male sexual dysfunction. Urol Clin N Am 1988; 15: 23.
21. Martín EL, Bennett AH.: Iatrogenic causes of impotence. In: Impotence: Diagnosis and Management of Erectile Dysfunction: 135. A.H. Bennett. W.B. Saunders, Philadelphia 1994.
22. Gasior BL, Levine FJ, Howannesian A, Krane RJ, Goldstein I.: Plaque-associated corporal veno-occlusive dysfunction in idiopathic Peyronie's disease: A pharmacocavernosometric and pharmacocavernosographic study. World J Urol 1990; 8 (2): 90.
23. Nehra A, Moreland RB.: Neurologic erectile dysfunction. Urol Clin North Am 2001 may; 28 (2): 289308.
24. Morehouse D.: Management of prostatomembranoux urethral disruption: 13 year experience. J Urol 1980; 123: 173.
25. Goldstein I, Hatzichistou D, Pescatori E.: Pelvic, perineal and penile trauma-associated arteriogenic impotence: pathophisiologic mechanism and the role of microvascular bypass surgery. In: Impotence: Diagnosis and Management of Erectile Dysfunction: 213. A.H. Bennett. Philadelphia: W.B. Saunders Co., 1994.
26. Munarriz R, Nehra A, Udelson D, Goldstein I.: Blunt trauma: the pathophysiology of hemodynamic injury leanding to erectile dysfunction. J Urol 1995; 153: 1.831.
27. Rodríguez Vela L, Acha Pérez J.: Disfunción eréctil asociada a endocrinopatías y diabetes. En: Erección, Eyaculación y sus Trastornos: 187. Sáenz de Tejada I. y Allona A. (Eds). Fomento Salud, Madrid 1997.
28. Leonard PL, Nickel CJ, Morales A.: Hiperprolactinemia and impotence. Why, when and how to investigate. J Urol 1989; 142: 992-995.
29. Ra S, Matsuzaka J, Sato F.: Prolactyn and growth hormone directly supress relaxation or produce contraction of the corpus cavernosum penis in vitro and in the vivo in the dog. J Urol 1995; 153: 858A.
30. Sáenz De Tejada I, Goldstein I.: Diabetic penile neuropathy. Urol Clin N Am 1988; 15: 17.
31. Meuleman E.: The role of penile biopsies in the evaluation of erectile dysfunction: a histo-morphometric strudy of the human cavernous body. Int J Impotence Res 1990; 2 (Supplement 2): 230.
32. Farré Martín JM.: Aspectos psicológicos de la disfunción eréctil y eyaculación precoz. En: Actualizacién en Andrología. Cap: 12. L. Rodríguez Vela y L.A. Rioja Sanz (Eds). Ediciones Pulso. Barcelona 1998.
33. Chun J, Carson CC 3rd. Physician-patient dialogue and clinical evaluation of erectile dysfunction. Urol Clin North Am 2001; 28 (2): 249-258.
34. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A.: The International Index on Erectil Function (IIEF): A multidimensional scale for assessment for erectile dysfunction. Urology 1997; 49: 822-830.
35. Rodríguez Vela L, Gonzalvo A, Gil P.: Evaluación inicial del paciente impotente. Manejo diagnóstico y terapéutico. En: L. Rodríguez Vela y L.A. Rioja eds. Actualización en Andrología. Barcelona: Pulso, 2000.
36. García Reboll L, Jiménez Cruz JF.: Evaluación vascular del paciente con disfunción eréctil. En: Rodríguez Vela, L. y Rioja Sanz, L. eds. Actualización en Andrología. Ed. Pulso. Barcelona, 2000.
37. Hartmut P, Jens EA, Dietmar B, Walter T.: Dynamic cavernosography: Venous outflow studies of cavernous bodies. J Urol 1985; 134: 276-279.
38. Karacan I, Howell JW.: Use of nocturnal penile tumescence in diagnosis of male erection dysfunction. In: Contemporary Management of Impotence and Infertility: 95. Tanagho E.A., Lue T.F. and McClure R.D. (Eds.). Williams and Wilkens. Baltimore, 1988.
39. Morales A, Harris C, Condra M, Heaton JP.: Validation of visual sexual stimulation in the etiological diagnosis of impotence. Int J Impotence Res 1990; 2: 109.
40. Goldstein.: Revascularización microquirúrgica peneana. En: Erección, Eyaculación y sus Trastornos: 369. Sáenz de Tejada I. y Allona A. (Eds). Fomento Salud, Madrid 1997.
41. Morales A, Heaton JP.: Hormonal erectile dysfunction. Evaluation and management. Urol Clin North Am 2001; 28: 279-288.
42. Amaya J, Rodríguez Vela L.: Disfunción eréctil: Endocrinopatías y diabetes. En: Rodríguez Vela, L. y Rioja Sanz, L. eds. Actualización en Andrología. Ed. Pulso. Barcelona, 2000.
43. Mcclure RD, Oses R, Ernest ML.: Hypogonadal impotence by transdermal testosterone. Urology 1991; 37: 224.
44. Montague DK, Barada JH, Belker AM, Levine LA, Nadig PW, Roehrborn CG, Sharlip ID, Bennett AH.: Clinical guidelines panel on erectile dysfunction: Summary report of organic erection dsyfunction. J Urol 1996; 156: 2.007-2.011.
45. Ernst E, Pittler MH.: Yohimbine for erectile dysfunction: A systematic review and meta-analysis of randomized clinical trials. J Urol 1998; 159: 433-436.
46. Perskircioglu L.: The role of pentoxifiline in the treatment of erectile disfunction DVE to bordeline arterial insufficiency. Br J Urol 1996; 77: 563.
47. Boolell M, Gepi-Atee S, Gingell JC, Allen MJ.: Sildenafil, a novel effective therapy for male erectile dysfunction. Br J Urol 1996; 78: 257-261.
48. Buvat J, Gingell CG, Jardin A, Olsson AM, Dinsmore WW, Kirkpatrick CK, Mayton MC, Orr M, Osterloh IH.: Sildenafil (Viagra) an oral treatment for erectile dysfunction: 1 year, open-label, extension study. J Urol 1997; 157 (Suppl): 204.
49. Lue TF.: Sildenafil study group: A study of sildenafil, a new oral agentent for treatmennt of male erectile dysfunction. J Urol 1997; 157 (Suppl): 181.
50. Goldstein I, Lue T, Padma-Nathan H, Rosen R, Steers W, Wicker P.: Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338 (20): 1.397.
51. Rendell MS, Rajfer J, Wicker PA, Smith MD.: Sildenafil for treatment of erectile dysfunction in men with diabetes. JAMA 1999; 281: 421-426.
52. Derry F, Gardner BP, Glass C, Fraser M, Dinsmore WW, Muirhead G, Maytom MC, Orr M.: Sildenafil (Viagra): A double-blind, placebo-controlled, single-dose, two-way crossover study in men with erectile dysfunction caused by traumatic spinal cord injury. J Urol 1997; 157 (supppl): 181.
53. Padma-Nathan H, Giuliano F.: Oral drug therapy for erectile dysfunction. Urol Clin North Am 2001; 28: 321-334.
54. Sildenafil improved sexual function in erectile dysfunction. ACP Journal Club 1998; 129: 70.
55. Morales A.: Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int J Impotence Res 1998; 10: 69.
56. Heaton JP, Adams MA, Morales A.: Apomorphine S.L. Is effective in the treatment of non-organic erectile dysfunction: results of a multicenter trial. Int J Impotence Res 1996; 8: 115.
57. Montorsi F, Salonia A, Scifo P.: Human cerebral activation by apomorphine after neural and erotic visual stimulation: Results of a double blind, placebo controlled study with functional MRI of the brain. Eur Urol 2001; 39 (suppl 5): 106.
58. Padma-Nathan H and Apomorfine SL Study Group: Efficacy and safety of apomorfine SL versus placebo for male erectile dysfuction. J Urol 1999; 161 (suppl): 214.
59. Dula E, Bukofzer S, Perdok R, George M, Apomorphine SL Study Group. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 2001; 39: 558-563.
60. Gadau M, Fernández A, Cuevas P, Martins T, Angulo J.: Tadalafil (IC 351) enhances NO-mediated relaxation of human arterial and trabecular penile smooth muscle. Eur Urol 2001; 39 (suppl 5): 106.
61. Padma-Nathan H, Rosen RC.: Tadalafil (IC 351) provides prompt response and extended period of responsiveness for the treatment of men with erectile dysfunction. Int J Impot Res 2001; 13 (suppl 4): 88.
62. Padma-Nathan H, Mcmurray JG, Pullman WE, Whitaker JS, Saoud JB, Ferguson KM, Rosen RC.: IC351 on-demand dosing study group. On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 2001; 13 (1): 2-9.
63. Sáenz De Tejada I, Emmick J, Fredlund P, Pullman W.: The effect on-demand IC351 treatment of erectile dysfunction in men with diabetes. Eur Urol 2001; 39 (suppl 5): 56.
64. Angulo J, Sáenz De Tejada I.: Potenciación de la relajación mediada por óxido nítrico en el músculo liso trabecular del pene humano por el inhibidor de la PDE 5, vardenafilo. Act Urol Esp 2001; 25 (5): 101 P.
65. Bischoff E.: The oral efficacy of vardenafil hydrochloride for inducing penile erection in a conscious rabbit model. J Urol 2001; 165: 1.316-1.318.
66. Klotz T, Sachse R, Heidrich A, Jockenhovel F, Rohde G, Wensing G, Horstmann R, Engelmann R.: Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: A Rigiscan and pharmacokinetic study. World J Urol 2001; 19: 32-39.
67. Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E, Bandel T.: The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: The first at-home clinical trial. Int J Impot Res 2001; 13: 192-199.
68. Levine LA, Dimitriou RJ.: Vacuum constriction and external erection devices in erectile dysfunction. Urol Clin North Am 2001; 28: 335-341.
69. Porst H.: The rationale for prostaglandin E1 in erectile faillure: a survey of worldwide. J Urol 1996; 155: 802.
70. Rodríguez Vela L, Moncada I, Gonzalvo A, Sáenz De Tejada I.: Tratamiento de la disfunción eréctil mediante farmacoterapia intracavernosa. Act Urol Esp 1998; 22 (4): 291-319.
71. Leungwattanakij S, Flynn V Jr, Hellstrom WJ.: Intracavernosal injection and intraurethral therapy for erectile dysfunction. Urol Clin North Am 2001; 28: 343-354.
72. Padma-Nathan H, Hellstrom WJ, Kaiser FE, Labasky RF, Lue TF, Nolten WE, Norwood PC, Peterson CA, Tam PY.: Treatment of men with erectile dysfuction with transurethral alprostadil. Medicated urethral system for erection study group. N Engl J Med 1997; 336 (1): 1.
73. Transurethral alprostadil restored potency in impotent men. ACP Journal Club 1997 jul-aug; 127: 7.
74. Goldstein I, Payton TR, Schechter PJ.: A double-blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the in-office treatment of erectile dysfunction. Urology 2001; 57: 301-305.
75. Allona Almagro A.: Prótesis de pene. En: Erección, Eyaculación y sus Trastornos: 419. Sáenz de Tejada I. y Allona A. (Eds). Fomento Salud, Madrid 1997.